Title:
HUMAN LUNG CANCER ASSOCIATED GENE SEQUENCES AND POLYPEPTIDES
Document Type and Number:
WIPO Patent Application WO/2000/055180
Kind Code:
A2
Abstract:
This invention relates to newly identified lung or lung cancer related polynucleotides and the polypetides encoded by these polynucleotides herein collectively known as 'lung cancer antigens', and to the complete gene sequences associated therewith and to the expression products thereof, as well as the use of such lung cancer antigens for detection, prevention and treatment of disorders of the lung, particularly the presence of lung cancer. This invention relates to the lung cancer antigens as well as vectors, host cells, antibodies directed to lung cancer antigens and recombinant and synthetic methods for producing the same. Also provided are diagnostic methods for diagnosing and treating, preventing and/or prognosing disorders related to the lung, including lung cancer, and therapeutic methods for treating such disorders. The invention further relates to screening methods for identifying agonists and antagonists of lung cancer antigens of the invention. The present invention further relates to methods and/or compositions for inhibiting the production and/or function of the polypetides of the present invention.
More Like This:
Inventors:
RUBEN STEVEN M (US)
Application Number:
PCT/US2000/005918
Publication Date:
September 21, 2000
Filing Date:
March 08, 2000
Export Citation:
Assignee:
HUMAN GENOME SCIENCES INC (US)
ROSEN CRAIG A (US)
RUBEN STEVEN M (US)
ROSEN CRAIG A (US)
RUBEN STEVEN M (US)
International Classes:
G01N33/50; A61K31/7088; A61K31/711; A61K35/76; A61K38/00; A61K39/395; A61K45/00; A61K48/00; A61P1/18; A61P9/00; A61P9/06; A61P9/10; A61P9/12; A61P13/08; A61P17/02; A61P25/00; A61P25/06; A61P27/02; A61P29/00; A61P35/00; C07K14/47; C07K14/82; C07K16/18; C07K16/32; C12N1/15; C12N1/19; C12N1/21; C12N5/10; C12N15/09; C12N15/12; C12P21/00; C12P21/02; C12P21/08; C12Q1/02; C12Q1/68; G01N33/15; G01N33/53; G01N33/531; G01N33/566; G01N33/574; G01N33/577; G01N33/68; G01N37/00; A61K39/00; (IPC1-7): C07K/
Other References:
GERHOLD ET AL.: 'It's the genes! EST access to human genome content' BIOESSAYS vol. 18, no. 12, 1996, pages 973 - 981, XP002933070
Attorney, Agent or Firm:
Wales, Michele M. (Inc. 9410 Key West Avenue Rockville, MD, US)
Download PDF:
Claims:
What Is Claimed Is :
| 1. | An isolated nucleic acid molecule comprising a polynucleotide having a nucleotide sequence at least 95% identical to a sequence selected from the group consisting of : (a) a polynucleotide fragment of SEQ ID NO: X or a polynucleotide fragment of the cDNA sequence included in the related cDNA clone, which is hybridizable to SEQ ID NO: X; (b) a polynucleotide encoding a polypeptide fragment of SEQ ID NO: Y or a polypeptide fragment encoded by the cDNA sequence included in the related cDNA clone, which is hybridizable to SEQ ID NO: X; (c) a polynucleotide encoding a polypeptide fragment of a polypeptide encoded by SEQ ID NO: X or a polypeptide fragment encoded by the cDNA sequence included in the related cDNA clone, which is hybridizable to SEQ ID NO: X; (d) a polynucleotide encoding a polypeptide domain of SEQ ID NO: Y or a polypeptide domain encoded by the cDNA sequence included in the related cDNA clone, which is hybridizable to SEQ ID NO: X; (e) a polynucleotide encoding a polypeptide epitope of SEQ ID NO: Y or a polypeptide epitope encoded by the cDNA sequence included in the related cDNA clone, which is hybridizable to SEQ ID NO: X; (f) a polynucleotide encoding a polypeptide of SEQ ID NO: Y or the cDNA sequence included in the related cDNA clone, which is hybridizable to SEQ ID NO: X, having biological activity; (g) a polynucleotide which is a variant of SEQ ID NO: X; (h) a polynucleotide which is an allelic variant of SEQ ID NO: X; (i) a polynucleotide which encodes a species homologue of the SEQ ID NO:Y; (j) a polynucleotide capable of hybridizing under stringent conditions to any one of the polynucleotides specified in (a) (i), wherein said polynucleotide does not hybridize under stringent conditions to a nucleic acid molecule having a nucleotide sequence of only A residues or of only T residues. |
| 2. | The isolated nucleic acid molecule of claim 1, wherein the polynucleotide fragment comprises a nucleotide sequence encoding a protein. |
| 3. | The isolated nucleic acid molecule of claim 1, wherein the polynucleotide fragment comprises a nucleotide sequence encoding the sequence identified as SEQ ID NO: Y or the polypeptide encoded by the cDNA sequence included in the related cDNA clone, which is hybridizable to SEQ ID NO: X. |
| 4. | The isolated nucleic acid molecule of claim 1, wherein the polynucleotide fragment comprises the entire nucleotide sequence of SEQ ID NO: X or the cDNA sequence included in the related cDNA clone, which is hybridizable to SEQ ID NO: X. |
| 5. | The isolated nucleic acid molecule of claim 2, wherein the nucleotide sequence comprises sequential nucleotide deletions from either the Cterminus or the Nterminus. |
| 6. | The isolated nucleic acid molecule of claim 3, wherein the nucleotide sequence comprises sequential nucleotide deletions from either the Cterminus or the Nterminus. |
| 7. | A recombinant vector comprising the isolated nucleic acid molecule of claim 1. |
| 8. | A method of making a recombinant host cell comprising the isolated nucleic acid molecule of claim 1. |
| 9. | A recombinant host cell produced by the method of claim 8. |
| 10. | The recombinant host cell of claim 9 comprising vector sequences. |
| 11. | An isolated polypeptide comprising an amino acid sequence at least 95% identical to a sequence selected from the group consisting of : (a) a polypeptide fragment of SEQ ID NO: Y or of the sequence encoded by the cDNA included in the related cDNA clone; (b) a polypeptide fragment of SEQ ID NO: Y or of the sequence encoded by the cDNA included in the related cDNA clone, having biological activity; (c) a polypeptide domain of SEQ ID NO: Y or of the sequence encoded by the cDNA included in the related cDNA clone; (d) a polypeptide epitope of SEQ ID NO: Y or of the sequence encoded by the cDNA included in the related cDNA clone; (e) a full length protein of SEQ ID NO: Y or of the sequence encoded by the cDNA included in the related cDNA clone; (f) a variant of SEQ ID NO: Y; (g) an allelic variant of SEQ ID NO: Y; or (h) a species homologue of the SEQ ID NO: Y. |
| 12. | The isolated polypeptide of claim 11, wherein the full length protein comprises sequential amino acid deletions from either the Cterminus or the N terminus. |
| 13. | An isolated antibody that binds specifically to the isolated polypeptide of claim 11. |
| 14. | A recombinant host cell that expresses the isolated polypeptide of claim 11. |
| 15. | A method of making an isolated polypeptide comprising: (a) culturing the recombinant host cell of claim 14 under conditions such that said polypeptide is expressed; and (b) recovering said polypeptide. |
| 16. | The polypeptide produced by claim 15. |
| 17. | A method for preventing, treating, or ameliorating a medical condition, comprising administering to a mammalian subject a therapeutically effective amount of the polypeptide of claim 11 or the polynucleotide of claim 1. |
| 18. | A method of diagnosing a pathological condition or a susceptibility to a pathological condition in a subject comprising: (a) determining the presence or absence of a mutation in the polynucleotide of claim 1; and (b) diagnosing a pathological condition or a susceptibility to a pathological condition based on the presence or absence of said mutation. |
| 19. | A method of diagnosing a pathological condition or a susceptibility to a pathological condition in a subject comprising: (a) determining the presence or amount of expression of the polypeptide of claim 11 in a biological sample; and (b) diagnosing a pathological condition or a susceptibility to a pathological condition based on the presence or amount of expression of the polypeptide. |
| 20. | A method for identifying a binding partner to the polypeptide of claim 11 comprising: (a) contacting the polypeptide of claim 11 with a binding partner; and (b) determining whether the binding partner effects an activity of the polypeptide. |
| 21. | The gene corresponding to the cDNA sequence of SEQ ID NO: Y. |
| 22. | A method of identifying an activity in a biological assay, wherein the methodcomprises: (a) expressing SEQ ID NO: X in a cell; (b) isolating the supernatant; (c) detecting an activity in a biological assay; and (d) identifying the protein in the supernatant having the activity. |
| 23. | The product produced by the method of claim 20. |
Description:
INTERNATIONALSEARCIIREPORTInternationalapplicationNo. PCT/USOO/05918 BoxIObservationswherecertainclaimswerefoundunsearchable(Cont
inuationofitem1offirstsheet) Thisinternationalreporthasnotbeenestablishedinrespectofcerta
inclaimsunderArticle17(2)(a)forthefollowingreasons: 1.)-)ClaimsNos.: becausetheyrelatetosubjectmatternotrequiredtobesearchedbythi
sAuthority,namely: 2. F-1ClaimsNos.: becausetheyrelatetopartsoftheinternationalapplicationthatdon
otcomplywiththeprescribedrequirementstosuch anextentthatnomeaningfulinternationalsearchcanbecarriedout,s
pecifically: 3.1 ClaimsNos.: becausetheyaredependentclaimsandarenotdraftedinaccordancewit
hthesecondandthirdsentencesofRule6.4(a). BoxIIObservationswhereunityofinventionislacking(Continuation
ofitem2offirstsheet) ThisInternationalSearchingAuthorityfoundmultipleinventionsin
thisinternationalapplication,asfollows: PleaseSeeExtraSheet. 1.2 Asallrequiredadditionalsearchfeesweretimelypaidbytheapplican
t,thisinternationalsearchreportcoversallsearchable claims. 2.jAsallsearchableclaimscouldbesearchedwithouteffortjustifyi
nganadditionalfee,thisAuthoritydidnotinvitepayment ofanyadditionalfee. 3. F-IAsonlysomeoftherequiredadditionalsearchfeesweretimelypaid
bytheapplicant,thisinternationalsearchreportcovers onlythoseclaimsforwhichfeeswerepaid,specificallyclaimsNos.: 4.rNorequiredadditionalsearchfeesweretimelypaidbytheapplican
t.Consequently,thisinternationalsearchreportis restrictedtotheinventionfirstmentionedintheclaims;itiscovere
dbyclaimsNos.: 1-10,SEQ ID No.:l RemarkonProtestTheadditionalsearchfeeswereaccompaniedbytheap
plicant'sprotest. No protestaccompaniedthepaymentofadditionalsearchfees. INTERNATIONALSEARCHREPORTIntemational application No. PCT/US00/05918 BOX II. OBSERVATIONS WHERE UNITY OF INVENTION WAS LACKING This ISA found multiple inventions as follows: This application contains the following inventions or groups of inventions which are not so linked as to form a single general inventive concept under PCT Rule 13.1. In order for all inventions to be searched, the appropriate additional examination fees must be paid.
Group I, claims 1-10, drawn to nucleic acids, vectors, host cells and method of making recombinant cell using said nucleic acids.
Group II, claims 11,12 and 16 drawn to isolated polypeptides.
Group III, claim 13, drawn to antibody.
Group IV, claim 14, drawn to a host cell expressing polypeptide of Group II.
Group V, claim 15, drawn to method of making polypeptide.
Group VI, claim 17, drawn to method for polypeptide-based method of treatment.
Group VII, claim 18, drawn to polynucleotide-based method of diagnosing a pathological condition.
Group VIII, claim 19, drawn to polypeptide-based method of diagnosing a pathological condition.
Group IX, claim 20, drawn to polypeptide-based method of identifying a binding partner to the polypeptide and to a product determined by this method.
Group XI, claim 21, drawn to a gene.
Group XII, claims 22 and 23, drawn to polynucleotide-based method of identifying activity.
The inventions listed as Groups I-XII do not relate to a single general inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features for the following reasons: The inventions listed as Groups I-IV, XI are drawn to different products which they lack the same or corresponding special technical features. Groups VII, XII are different methods of use of the product of Group I. Groups VI, VIII, IX are different methods of use of the product of Group II. Group V is method of use of product of Group IV.
Sequence Election Requirement Applicable m All Groups In addition, each Group detailed above reads on distinct Groups drawn to multiple sequences. The sequences are distinct because they are unrelated sequences, and a further lack of unity is applied to each Group. The lack of unity is partially waived and the Applicants must further elect 10 sequences for examination in the elected Group detailed above.
Payment of fees for an additional invention will entitle the Applicants to examination of four additional sequences.